Sberbank continues to expand its medical direction. The company, together with the R-Pharm group, signed an agreement to purchase 90% of shares in the Internet pharmacy Eapteka. The partners will acquire 45% each after regulatory approvals, 10% will be retained by the founder and CEO of the company Anton Buzdalin. The amount of the transaction and its details were not disclosed. The company will continue to operate under the SberEapteka brand. The parties expect to close the deal in the Q4 2020.
Eapteka will be integrated into SberZdorovye, SberLogistics, a subscription with discounts for SberPrime services. In the future, the company also allows integration with other services from its ecosystem.
The bank explains that the emergence of Eapteka in the ecosystem is a consistent step towards the development of SberZdorovye. This area combines telemedicine, appointment service and other services. The company renamed the DocDoc medical service to SberZdorovye in June 2020. At the same time, the company announced the online sales of over-the-counter (OTC) drugs.
Original (in Russian)
Moscow News Agency